LL-37: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 40 studies and official documents checked

In short

LL-37 is a 37-amino-acid peptide the body makes as part of its immune defense, and lab-made copies are sold online. Unlike many peptides sold that way, it has been tested in people, mostly as a liquid or cream put on ulcers. The results split: in 34 people with leg ulcers it sped healing at the two lower strengths, but a later trial of 148 found no overall benefit. A 2023 foot-ulcer trial found more tissue growth. A 2023 trial of an oral form in 238 COVID inpatients found a benefit only when it was started early, and four people with melanoma had it injected into tumors. We found no study of injecting it under the skin for immunity, infections or general health. In dishes and animals the same peptide also drives psoriasis-, lupus- and rosacea-like inflammation, and it helps or hurts tumors depending on the tissue. It isn’t FDA-approved, and the FDA says it lacks safety information.

EvidenceCellAnimalHumanhuman studies are on wounds, one oral form and tumor injections; none of injection under the skin

You’ll often read that LL-37 balances the immune system, fights Lyme disease and mold, heals the gut, calms autoimmune disease and has an excellent safety record. This page covers what it is, what each human study tested, what the lab findings on autoimmune disease and cancer mean, and where it stands legally.

Names and forms you’ll see

The names on LL-37 products
Name What it is Studied in people?
LL-37, cathelicidin LL-37 The active piece, 37 amino acids long, cut from a larger body protein called hCAP18. It is the only cathelicidin in humans (Ridyard et al., 2021) Yes: ulcer, COVID and melanoma studies, below
Ropocamptide The international drug name the FDA’s substance registry lists for LL-37 (FDA GSRS) The same studies
KR-12, GF-17, GI-20, OP-145 Shorter or edited copies made in labs from LL-37; different peptides (Ridyard et al., 2021) Not the form in the human studies below
Vials, “supplements” and other products sold online Forms sold under the LL-37 name No study of these products found; see below for what was tested

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA’s registry lists LL-37 under the name ropocamptide.

LL-37 CAS numbers
Form CAS number Registry record
LL-37 (ropocamptide) 154947-66-7 FDA GSRS

What LL-37 is

LL-37 is made mostly by the cells that line skin, airways and gut, and by white blood cells. The body makes a larger protein and an enzyme cuts LL-37 from its end (Ridyard et al., 2021). In a dish it punches holes in bacterial membranes. It also signals to immune cells, raising or lowering inflammation depending on the setting, which is why one paper can call it an antibiotic and another an inflammation driver (Kahlenberg and Kaplan, 2013).

Most of what you’ll read is about the body’s own LL-37, or about how much of it people have in blood or skin. A study that measures LL-37 isn’t a study of taking it. The studies that gave LL-37 to people are the handful below.

What has been studied

In people: LL-37 given

Human studies of LL-37
Study Who What was used What it found
Grönberg et al., 2014 34 people with leg ulcers that wouldn’t heal; the first test in people; randomized, double-blind LL-37 solution on the ulcer twice a week for 4 weeks, at 0.5, 1.6 or 3.2 mg/ml, or placebo Healing was about 6 and 3 times faster than placebo at the two lower strengths (p = 0.003 and 0.088) and no different at the highest. No safety concerns
Mahlapuu et al., 2021 148 people with leg ulcers; phase IIb, randomized, double-blind, with compression LL-37 at 0.5 or 1.6 mg/ml, or placebo No significant improvement overall. A look afterward at ulcers of 10 cm² or more showed improvement. Well tolerated
Miranda et al., 2023 People with diabetic foot ulcers and mild infection; randomized, double-blind; the registry lists 40 (NCT04098562) LL-37 cream or placebo cream twice a week for 4 weeks More tissue growth (granulation) on days 7, 14, 21 and 28. IL-1-alpha and TNF-alpha weren’t lowered, and bacteria counts didn’t differ significantly
Zhao et al., 2023 238 adult COVID inpatients (Omicron BA.5.1.3); open-label, randomized, placebo-controlled, one hospital An oral form: engineered bacteria (Lactococcus lactis) that make LL-37; no amount in the abstract Time to a negative virus test was 9.8 days against 14.0 when started within 6 days of confirmation. No severe adverse events
NCT02225366 M.D. Anderson melanoma study: 4 people with melanoma in the skin enrolled, 3 started; phase 1/2 Weekly injections into tumors: 250 micrograms per tumor in the first group, 500 in the second Posted results list no serious adverse events; one person stopped for lack of efficacy. Other events listed include squamous cell carcinoma and actinic keratosis in one person each, in the lower-dose group
Dolkar et al., 2018 One woman, 63, with stage IIIC melanoma (a case report) Eight weekly injections of LL-37 into lesions Her injected lesions shrank, but about 45 days in she developed warty papules and a blistering lesion across her trunk and limbs; biopsies showed atypical skin-cell growth. All cleared within 2 months of stopping

Almost all of this is a solution or cream on a wound, one oral product and tumor injections. We found no study of LL-37 injected under the skin for immunity, infections, the gut or general health.

EvidenceCellAnimalHumanulcers, COVID inpatients and melanoma; not injection under the skin

In people: what their own LL-37 shows

  • Rosacea. People with rosacea have abnormally high cathelicidin in facial skin, and the pieces found there differ from those in healthy skin (Yamasaki et al., 2007).
  • Psoriasis. Two-thirds of people with moderate-to-severe plaque psoriasis have T cells aimed at LL-37, and the number tracks disease activity (Lande et al., 2014). In psoriasis, LL-37 turns the body’s own DNA into a trigger for interferon (Lande et al., 2007).
  • Lupus. Blood from lupus patients holds complexes of neutrophil peptides and the body’s own DNA, and the patients make antibodies against both (Lande et al., 2011).
  • Heart attack. Among 302 people after a heart attack, those with lower LL-37 in blood had more major cardiac events over 3 years (29.1% vs 12.6%) (Zhao et al., 2022).

These are measurements of the body’s own LL-37 in disease. They show it is tied to flares and, in one case, to better outcomes, but they aren’t tests of taking it.

In animals

  • Rosacea-like skin, 2007 and 2023. Injecting rosacea-type cathelicidin pieces into mouse skin raised inflammation (Yamasaki et al., 2007). Mice injected under the skin every 12 hours for 20 days got lesions that didn’t fully heal; after a short course they recovered fully (Zhang et al., 2023).
  • Alzheimer’s-type changes, 2022. In mouse and monkey models, LL-37 raised amyloid-beta, caused tangles, neuron loss and memory problems, through a channel called CLIC1 (Chen et al., 2022).
  • Tumors, 2009 and 2023. Blocking LL-37 slowed ovarian tumors grown in mice, partly by cutting the stem cells that join them (Coffelt et al., 2009). In mouse and human melanoma cells, LL-37 raised blood-vessel and invasion signals (Ohuchi et al., 2023). In gastric cancer it slowed growth in cells and in mice (Wu et al., 2010).
  • Gut, 2023 and 2024. LL-37 lowered injury scores in a mouse model of newborn gut disease, and protected the gut and improved survival in rats with heat stroke (Lueschow-Guijosa et al., 2024; Shih et al., 2023).
  • Where it goes, 2024. In mice, a labelled form given into a vein was cleared quickly by the liver, with some passing through the lungs; given under the skin it was absorbed into the body and cleared by the kidneys (Esposito et al., 2024).

EvidenceCellAnimalHuman

In dishes

  • Bacteria, 1998 and 2021. It stopped E. coli at 5 micromolar, but at 13 to 25 micromolar it was also toxic to several kinds of human cells, and human serum blocked both effects (Johansson et al., 1998). A 2021 review lists resistance after repeated exposure, weaker activity in body fluids, breakdown by enzymes, cost and toxicity to human cells as the problems (Ridyard et al., 2021).
  • Fungus, 2023. A 17-amino-acid piece of LL-37 killed Candida albicans, including with serum, saliva or urine added, and cleared biofilms. The paper highlights the piece, not LL-37 itself (Kalimuthu et al., 2023).
  • Herpes and other viruses, 2005 to 2025. LL-37 cut HSV-1 and adenovirus numbers in a direct test (Gordon et al., 2005). In cells already infected with HSV-1 it delayed spread but didn’t stop it (Lee et al., 2014). LL-37 made by HSV-2-infected skin cells made immune cells easier to infect with HIV (Ogawa et al., 2013). It binds the coronavirus spike protein, but a change found in Omicron weakens the binding (Bi et al., 2025).
  • The Lyme germ, 2002. Five related cathelicidin peptides, LL-37 among them, needed 307 to 449 mg/L to stop Borrelia (Sambri et al., 2002).
  • Sperm, 2014 and 2018. LL-37 and two shorter pieces killed mouse and human sperm in dishes, and in mice (Srakaew et al., 2014; Kiattiburut et al., 2018).
  • Gastric cancer cells, 2026. LL-37 lowered growth, blood-vessel formation and migration of gastric cancer cells and slowed tumors in mice (Luo et al., 2026).

EvidenceCellAnimalHuman

The usual claims, checked

Common LL-37 claims vs the studies
Claim Verdict What the studies found
It heals wounds and ulcers Mixed The trials split. In 34 people with leg ulcers, healing was about 6 and 3 times faster at the two lower strengths (p = 0.003 and 0.088) (Grönberg et al., 2014). In 148 people it didn’t improve healing overall (Mahlapuu et al., 2021). A 2023 foot-ulcer trial found more tissue growth (Miranda et al., 2023). Each applied it to the wound
It kills bacteria, including resistant ones and biofilms Mixed In dishes it kills many bacteria, but bacteria become resistant, it works less well in body fluids and it harms human cells at higher amounts (Ridyard et al., 2021; Johansson et al., 1998). In the foot-ulcer trial, bacteria counts didn’t differ significantly from placebo (Miranda et al., 2023). We found no trial showing it clears a bacterial infection
It kills fungus Untested A 17-amino-acid piece of LL-37 killed Candida in dishes, even with serum, saliva or urine added (Kalimuthu et al., 2023). We found no study in people
It fights herpes and other viruses Mixed In dishes it cut HSV-1 numbers (Gordon et al., 2005), but in cells already infected it only delayed spread (Lee et al., 2014), and LL-37 from HSV-2-infected skin cells raised HIV susceptibility (Ogawa et al., 2013). No study in people with herpes
It treats COVID or long COVID Mixed One open-label trial of 238 hospital patients found a shorter time to a negative test with an oral form started within 6 days (Zhao et al., 2023). A 2025 lab study found a change in Omicron weakens LL-37’s binding to the spike protein (Bi et al., 2025). We found no study of long COVID
It boosts or balances the immune system Untested It recruits immune cells and can raise or lower inflammation in dishes (Ridyard et al., 2021). We found no study that gave it to people and measured a general immune result
It calms autoimmune disease and chronic inflammation Contradicted The research points the other way. LL-37 turns the body’s own DNA into an interferon trigger in psoriasis, two-thirds of people with moderate-to-severe psoriasis have T cells aimed at it, and in lupus it sits in DNA complexes that drive autoantibodies (Lande et al., 2007; Lande et al., 2014; Lande et al., 2011). A review suggests blocking it may be the treatment (Kahlenberg and Kaplan, 2013)
It heals the gut (leaky gut, SIBO, bowel disease) Untested In a mouse model of newborn gut disease it lowered injury scores, and in rats with heat stroke it protected the gut (Lueschow-Guijosa et al., 2024; Shih et al., 2023). We found no study in people with any gut condition
It treats Lyme disease or mold illness Untested The only Lyme-germ test we found is a 2002 dish study of five related peptides, which needed 307 to 449 mg/L, far above the 5 micromolar (about 22 mg/L by our arithmetic) that stopped E. coli in another study (Sambri et al., 2002; Johansson et al., 1998). We found no study of mold, or of Lyme disease in people
It fights cancer Mixed It depends on the tissue. Blocking LL-37 slowed ovarian tumors in mice, and it raised invasion signals in melanoma cells (Coffelt et al., 2009; Ohuchi et al., 2023), while it slowed gastric cancer in cells and mice (Wu et al., 2010; Luo et al., 2026). The FDA says it may promote tumors in some tissues (FDA, 2026). The only human test is a 4-person melanoma study
It protects the brain and calms neuroinflammation Contradicted In the one study we found, LL-37 caused Alzheimer’s-type changes and memory problems in mice and monkeys (Chen et al., 2022). We found no study showing a benefit in the brain, and no repeat of that result
It has an excellent safety record, with only mild side effects Mixed Solutions on ulcers were well tolerated in 34 and 148 people (Grönberg et al., 2014; Mahlapuu et al., 2021). But a woman given weekly tumor injections developed skin lesions that cleared after she stopped (Dolkar et al., 2018), mice injected for 20 days got lasting rosacea-like lesions (Zhang et al., 2023), and the FDA says it lacks safety information (FDA, 2026). No safety study of injection under the skin
Vitamin D raises your own LL-37 Mixed The trials split. In 30 sepsis patients, LL-37 rose 30% on the higher dose against a 17% fall on placebo (Quraishi et al., 2015). In 129 pregnant women, vitamin D didn’t raise cord-blood LL-37 and lowered it in stimulated newborn cells (Raqib et al., 2014). In tuberculosis patients, the drug phenylbutyrate raised LL-37 in blood cells (Mily et al., 2015)
It works better stacked with KPV or thymosin alpha-1 Untested No study we found tested LL-37 with either. See the KPV page for that peptide’s own record
Injection schedules online come from research Untested The amounts in the human studies are a strength on an ulcer (0.5 to 3.2 mg/ml), a cream, and 250 or 500 micrograms per injection into a melanoma tumor (Grönberg et al., 2014; NCT02225366). We found no study of injection under the skin, or of a time of day or a cycle
It is FDA-approved Contradicted No. The FDA names it on its page of bulk substances that may present significant safety risks for compounding (FDA, 2026). A registry entry under the name ropocamptide isn’t an approval (FDA GSRS)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

What the studies used

Amounts used in the LL-37 studies
Study What was tested Amount reported
Grönberg et al., 2014 Leg ulcers; solution on the ulcer twice a week for 4 weeks 0.5, 1.6 and 3.2 mg/ml; the two lower strengths helped, the highest didn’t
Mahlapuu et al., 2021 Leg ulcers, with compression 0.5 and 1.6 mg/ml
Miranda et al., 2023 Diabetic foot ulcers; cream twice a week for 4 weeks The registry lists 0.5 mg/ml (NCT04098562)
NCT02225366 Melanoma; injections into tumors once a week 250 micrograms per tumor, then 500 in the next group
Zhao et al., 2023 COVID inpatients; an oral form made by bacteria Not given in the abstract
Johansson et al., 1998; Gordon et al., 2005 Dishes 5 micromolar stopped E. coli; 13 to 25 micromolar was toxic to several kinds of human cells without serum; another lab saw no toxicity to one lung cell line up to 111 micromolar
Esposito et al., 2024 Mice, a labelled form Just over 20 micrograms into a vein or under the skin

A strength on an ulcer or an amount per tumor isn’t a dose for any other use, and no study converts one into the other. We found no dose-finding or blood-level study of LL-37 in people. These are amounts from studies, not advice for anyone to use.

Side effects and safety

  • Put on ulcers. The solution was well tolerated, with no safety concerns, in 34 and 148 people (Grönberg et al., 2014; Mahlapuu et al., 2021). The oral COVID product showed no severe adverse events in 238 inpatients (Zhao et al., 2023).
  • Injected into tumors. The registry results list no serious events in the melanoma study, with squamous cell carcinoma and actinic keratosis among the other events (NCT02225366). One woman developed warty, blistering skin lesions about 45 days in, and they cleared within 2 months of stopping (Dolkar et al., 2018).
  • In animals. Repeated injections gave mice lasting rosacea-like lesions (Zhang et al., 2023), and LL-37 caused Alzheimer’s-type changes in mice and monkeys (Chen et al., 2022).
  • Autoimmune disease. LL-37 is a target of T cells in psoriasis and part of the DNA complexes in lupus, and rosacea skin holds too much of it (Lande et al., 2014; Lande et al., 2011; Yamasaki et al., 2007). We found no study of what taking it does in people with those conditions.
  • Fertility. It killed mouse and human sperm in dishes and in mice (Srakaew et al., 2014; Kiattiburut et al., 2018). The FDA cites male reproduction among its concerns (FDA, 2026).
  • Human cells. In dishes it is toxic to several kinds of human cells at higher amounts, and serum blocks that (Johansson et al., 1998).
  • What is in the bottle. We found no independent analysis of LL-37 vials or other products sold online.
  • Not studied. Pregnancy, children, long-term use, other medicines, injection under the skin, and use by people with autoimmune disease or cancer.

Side effects people report from online products aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not an approved drug. The FDA names cathelicidin LL-37 on its page of bulk substances that may present significant safety risks. It says it lacks enough safety information, that some routes may carry a risk of immune reaction, and that lab findings suggest harm to male reproduction and tumor promotion in some tissues (FDA, 2026).
  • A registry name isn’t an approval. The FDA’s substance registry lists LL-37 as ropocamptide (FDA GSRS).
  • Registered trials. ClinicalTrials.gov lists a melanoma study and a foot-ulcer cream study of LL-37 (NCT02225366; NCT04098562), plus many vitamin D studies that measure it (ClinicalTrials.gov search).
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Sport. The World Anti-Doping Agency’s 2026 list doesn’t name it, but its S0 class prohibits any substance with no government approval for human therapeutic use (WADA, 2026).
  • “Research use only” vials and any use in people aren’t approved.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • Measuring isn’t taking. Many LL-37 papers count the body’s own LL-37 in blood, skin or saliva. Check that a study gave LL-37 to someone.
  • Which form. A solution or cream on an ulcer, an oral bacteria product and tumor injections are different from a vial for injection under the skin. None of the human studies tested the last.
  • Which condition. A result in leg ulcers or COVID inpatients says nothing about Lyme disease, mold, the gut or autoimmune disease.
  • Both directions. LL-37 is tied to flares and to tumor growth in some studies. A page that lists only benefits has left them out.
  • Which peptide. KR-12, GF-17 and OP-145 are shorter or edited copies, not LL-37 (Ridyard et al., 2021).

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether injecting LL-37 under the skin does anything for immunity, infections, the gut or general health.
  • Whether the leg-ulcer benefit is real, since the two trials split and the benefit in large ulcers came from a look afterward.
  • Whether the oral COVID result holds in a blinded trial, given that lab work says Omicron escapes LL-37.
  • What repeated or injected use does in people with psoriasis, lupus, rosacea or cancer.
  • What blood levels any amount produces in a person, and what is in the products sold online.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention LL-37. We recheck every month. Last checked Nov 12, 2026.

Flagged studies that mention LL-37

Retracted, withdrawn and flagged studies
Study What it was about Status
Feng et al., 2024 Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the modulation of SIRT3-SOD2-NF-κB signaling pathway. Retracted (2026) · notice
Farsi et al., 2021 A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis. Retracted (2022) · notice
Mohammad et al., 2021 A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. Retracted (2025) · notice
Li et al., 2018 The therapeutic effect of artesunate on rosacea through the inhibition of the JAK/STAT signaling pathway. Retracted (2024) · notice
Guo et al., 2016 Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on Streptococcus mutans. Retracted (2017) · notice
Girnita et al., 2012 Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Retracted (2023) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Johansson et al., 1998 J Biol Chem No retraction or concern
Sambri et al., 2002 J Antimicrob Chemother No retraction or concern
Gordon et al., 2005 Curr Eye Res No retraction or concern
Yamasaki et al., 2007 Nat Med No retraction or concern
Lande et al., 2007 Nature No retraction or concern
Coffelt et al., 2009 Proc Natl Acad Sci U S A No retraction or concern
Wu et al., 2010 J Cell Physiol No retraction or concern
Lande et al., 2011 Sci Transl Med No retraction or concern
Ogawa et al., 2013 Cell Host Microbe No retraction or concern
Kahlenberg and Kaplan, 2013 J Immunol No retraction or concern
Srakaew et al., 2014 Hum Reprod No retraction or concern
Lee et al., 2014 Transl Vis Sci Technol No retraction or concern
Grönberg et al., 2014 Wound Repair Regen No retraction or concern
Raqib et al., 2014 Br J Nutr No retraction or concern
Lande et al., 2014 Nat Commun No retraction or concern
Quraishi et al., 2015 Crit Care Med No retraction or concern
Mily et al., 2015 PLoS One No retraction or concern
Dolkar et al., 2018 J Cutan Pathol No retraction or concern
Kiattiburut et al., 2018 Hum Reprod No retraction or concern
Ridyard and Overhage, 2021 Antibiotics (Basel) No retraction or concern
Mahlapuu et al., 2021 Wound Repair Regen No retraction or concern
Zhao et al., 2022 J Atheroscler Thromb No retraction or concern
Chen et al., 2022 Mol Psychiatry No retraction or concern
Shih et al., 2023 Biomed Pharmacother No retraction or concern
Ohuchi et al., 2023 Cancers (Basel) No retraction or concern
Kalimuthu et al., 2023 APMIS No retraction or concern
Zhang et al., 2023 Curr Issues Mol Biol No retraction or concern
Miranda et al., 2023 Arch Dermatol Res No retraction or concern
Zhao et al., 2023 J Med Virol No retraction or concern
Lueschow-Guijosa et al., 2024 iScience No retraction or concern
Esposito et al., 2024 Eur J Pharm Biopharm No retraction or concern
Bi et al., 2025 Cell Prolif No retraction or concern
Luo et al., 2026 Histol Histopathol No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is LL-37?

A 37-amino-acid peptide the body makes as part of its immune defense. It is the only human member of the cathelicidin family, and it is cut from a larger protein called hCAP18 (Ridyard et al., 2021). Lab-made copies are sold online.

What does LL-37 peptide do?

In dishes it kills many bacteria and signals to immune cells. In people, studies put it on ulcers, tested an oral form in COVID inpatients and injected it into melanoma tumors (Grönberg et al., 2014; Zhao et al., 2023). It also drives inflammation in psoriasis, lupus and rosacea.

Is LL-37 peptide safe?

Not shown for injection. Solutions on ulcers were well tolerated in 34 and 148 people, but one woman had skin lesions after tumor injections, mice injected for 20 days got lasting rosacea-like lesions, and the FDA says it lacks safety information (Grönberg et al., 2014; Dolkar et al., 2018; Zhang et al., 2023).

What are the side effects of LL-37?

No serious ones were listed in the melanoma study registry, though squamous cell carcinoma and actinic keratosis were among the events, and one woman had warty skin lesions (NCT02225366; Dolkar et al., 2018). Side effects people report from online products come from users, not studies.

Does LL-37 heal wounds?

The evidence is mixed. Two leg-ulcer trials split, and a foot-ulcer trial found more tissue growth. Each applied it to the wound (Grönberg et al., 2014; Mahlapuu et al., 2021; Miranda et al., 2023).

Does LL-37 kill bacteria, fungus or viruses?

In dishes it kills many bacteria and a fungus piece killed Candida, but there are limits: resistance, weaker activity in body fluids and toxicity to human cells (Ridyard et al., 2021; Kalimuthu et al., 2023). We found no trial showing it clears a bacterial or fungal infection.

Can LL-37 treat herpes?

Not shown. In dishes it cut HSV-1 numbers but only delayed spread in infected cells, and we found no study in people with herpes (Gordon et al., 2005; Lee et al., 2014).

Does LL-37 cause or fight cancer?

Studies go both ways. Blocking it slowed ovarian tumors in mice and it raised invasion signals in melanoma cells, but it slowed gastric cancer in cells and mice. The FDA says it may promote tumors in some tissues (Coffelt et al., 2009; Wu et al., 2010).

Is LL-37 linked to psoriasis, rosacea or lupus?

Yes, as a driver, not a cure. It turns the body’s own DNA into an interferon trigger in psoriasis, two-thirds of psoriasis patients have T cells aimed at it, and rosacea skin holds too much of it (Lande et al., 2007; Lande et al., 2014; Yamasaki et al., 2007).

What time of day to take LL-37?

We don’t give dosing advice. We found no study that tested a time of day for any form. The ulcer trials put it on the wound twice a week (Grönberg et al., 2014).

What is the LL-37 dosage?

We don’t give dosing advice. The amounts in the studies are strengths on an ulcer, 0.5 to 3.2 mg/ml, and 250 or 500 micrograms per tumor injection (Grönberg et al., 2014; NCT02225366). We found no dose study of injection under the skin.

Can you inject LL-37?

The only injections in people we found were into melanoma tumors, in a registry study with four people enrolled (NCT02225366). We found no study of injection under the skin for any other use.

Can you take LL-37 by mouth or as a supplement?

One trial gave 238 COVID inpatients an oral form made by engineered bacteria, which shortened time to a negative test only when started within 6 days (Zhao et al., 2023). We found no other trial of an oral LL-37 product.

Is LL-37 the same as cathelicidin?

LL-37 is the active piece of the human cathelicidin protein. Humans have only one cathelicidin, and LL-37 is cut from it (Ridyard et al., 2021).

Can vitamin D raise LL-37?

The trials split. It rose in sepsis patients on a higher dose, but vitamin D didn’t raise cord-blood LL-37 in pregnant women (Quraishi et al., 2015; Raqib et al., 2014).

Can LL-37 be stacked with KPV or thymosin alpha-1?

No study we found tested it. See the KPV page for that peptide’s own record.

Is LL-37 FDA approved or legal?

It isn’t an approved drug, and the FDA names it on its page of bulk substances that may present significant safety risks (FDA, 2026). Our guide to what to look for covers the routes people use.

Sources

  1. Grönberg A, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613-21. PubMed 25041740
  2. Mahlapuu M, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021;29(6):938-950. PubMed 34687253
  3. Miranda E, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023;315(9):2623-2633. PubMed 37480520
  4. Zhao Y, et al. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol. 2023;95(8):e29035. PubMed 37605995
  5. Dolkar T, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018;45(7):539-544. PubMed 29665030
  6. Yamasaki K, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-80. PubMed 17676051
  7. Zhang C, et al. Long-Term Administration of LL-37 Can Induce Irreversible Rosacea-like Lesion. Curr Issues Mol Biol. 2023;45(4):2703-2716. PubMed 37185701
  8. Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-9. PubMed 17873860
  9. Lande R, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. PubMed 25470744
  10. Lande R, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19. PubMed 21389263
  11. Zhao H, et al. High Human Antimicrobial Peptide LL-37 Level Predicts Lower Major Adverse Cardiovascular Events after an Acute ST-Segment Elevation Myocardial Infarction. J Atheroscler Thromb. 2022;29(10):1499-1510. PubMed 34853213
  12. Coffelt SB, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A. 2009;106(10):3806-11. PubMed 19234121
  13. Wu WK, et al. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol. 2010;223(1):178-86. PubMed 20054823
  14. Luo H, et al. Cathelicidin LL-37 inhibits angiogenesis and migration in gastric cancer via inhibition of NF-κB/IL-6 signaling. Histol Histopathol. 2026:25135. PubMed 42745581
  15. Ohuchi K, et al. LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages. Cancers (Basel). 2023;15(6):1678. PubMed 36980564
  16. Chen X, et al. Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression. Mol Psychiatry. 2022;27(11):4790-4799. PubMed 36138130
  17. Srakaew N, et al. Antimicrobial host defence peptide, LL-37, as a potential vaginal contraceptive. Hum Reprod. 2014;29(4):683-96. PubMed 24549217
  18. Kiattiburut W, et al. Antimicrobial peptide LL-37 and its truncated forms, GI-20 and GF-17, exert spermicidal effects and microbicidal activity against Neisseria gonorrhoeae. Hum Reprod. 2018;33(12):2175-2183. PubMed 30357408
  19. Esposito TVF, et al. Biodistribution of the cationic host defense peptide LL-37 using SPECT/CT. Eur J Pharm Biopharm. 2024;202:114398. PubMed 38972467
  20. Ridyard KE, et al. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel). 2021;10(6):650. PubMed 34072318
  21. Johansson J, et al. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem. 1998;273(6):3718-24. PubMed 9452503
  22. Gordon YJ, et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005;30(5):385-94. PubMed 16020269
  23. Lee CJ, et al. Cathelicidin LL-37 and HSV-1 Corneal Infection: Peptide Versus Gene Therapy. Transl Vis Sci Technol. 2014;3(3):4. PubMed 24932432
  24. Ogawa Y, et al. Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. Cell Host Microbe. 2013;13(1):77-86. PubMed 23332157
  25. Bi Z, et al. LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants. Cell Prolif. 2025;58(12):e70060. PubMed 40375579
  26. Kalimuthu S, et al. A heptadeca amino acid peptide subunit of cathelicidin LL-37 has previously unreported antifungal activity. APMIS. 2023;131(11):584-600. PubMed 37150907
  27. Sambri V, et al. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J Antimicrob Chemother. 2002;50(6):895-902. PubMed 12461010
  28. Lueschow-Guijosa SR, et al. Host defense peptides human β defensin 2 and LL-37 ameliorate murine necrotizing enterocolitis. iScience. 2024;27(6):109993. PubMed 38846005
  29. Shih CC, et al. Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke. Biomed Pharmacother. 2023;161:114565. PubMed 36958193
  30. Mily A, et al. Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS One. 2015;10(9):e0138340. PubMed 26394045
  31. Raqib R, et al. Prenatal vitamin D₃ supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity. Br J Nutr. 2014;112(6):908-15. PubMed 25089537
  32. Quraishi SA, et al. Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. Crit Care Med. 2015;43(9):1928-37. PubMed 26086941
  33. Kahlenberg JM, et al. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895-901. PubMed 24185823
  34. ClinicalTrials.gov. Search for LL-37, November 12, 2026: a melanoma study and a foot-ulcer cream study of LL-37 itself, plus vitamin D, probiotic and other studies that measure it. Search
  35. ClinicalTrials.gov. NCT02225366: Induction of antitumor response in melanoma patients using the antimicrobial peptide LL37 (M.D. Anderson Cancer Center), results posted. Record
  36. ClinicalTrials.gov. NCT04098562: The efficacy of LL-37 cream on aerobic bacteria colonization pattern, inflammation response and healing rate of diabetic foot ulcer (Universitas Indonesia). Record
  37. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  38. World Anti-Doping Agency. 2026 Prohibited List. WADA document
  39. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  40. U.S. Food and Drug Administration. Global Substance Registration System: Ropocamptide (UNII 3DD771JO2H). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.